CN111773328A

CN111773328A - Traditional Chinese medicine composition for treating prosopalgia and application thereof

Info

Publication number: CN111773328A
Application number: CN202010840518.1A
Authority: CN
Inventors: 王永华; 梁晟楠; 郭子湖; 黄超; 陈学通; 郑春丽
Original assignee: Northwestern University
Current assignee: Northwestern University
Priority date: 2020-08-20
Filing date: 2020-08-20
Publication date: 2020-10-16

Abstract

The invention discloses a traditional Chinese medicine composition for treating prosopalgia and application thereof. The traditional Chinese medicine composition comprises the following components in parts by mass: 1-10 parts of radix achyranthis bidentatae, 1-10 parts of radix aconiti agrestis, 1-10 parts of radix notoginseng lophatheri, 1-10 parts of radix notoginseng pentandrae, 1-10 parts of rhizoma gastrodiae, 1-10 parts of radix angelicae, 1-10 parts of asarum, 1-10 parts of scorpion and 1-10 parts of stiff silkworm. The traditional Chinese medicine composition can be used as a medicine for treating trigeminal neuralgia, or the traditional Chinese medicine composition can be used for preparing a medicine for treating trigeminal neuralgia, and the dosage forms of the medicine comprise decoction, pills, powder, granules, tablets, capsules and oral liquid. The invention has simple compatibility and preparation process, no toxic or side effect, short treatment course and lower cost, can effectively cure trigeminal neuralgia and is not easy to relapse, and the effective rate reaches 98%.

Description

Traditional Chinese medicine composition for treating prosopalgia and application thereof

Technical Field

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating prosopalgia and application thereof.

Background

Trigeminal Neuralgia (TN), also known as painful convulsion, is the most common cranial nerve disease, a recurrent transient paroxysmal megalgia confined to the innervated area of the trigeminal nerve. The disease is divided into primary trigeminal neuralgia (also called idiopathic trigeminal neuralgia) and secondary trigeminal neuralgia (also called symptom trigeminal neuralgia), and has no infectivity and heredity. According to statistics, adults and old people are the main group of diseases, the disease onset age is 28-89 years old, wherein 70% -80% of the disease onset age is over 40 years old, the peak age is 48-59 years old, and women are more prone to trigeminal neuralgia than men.

At present, the methods or medicines for treating trigeminal neuralgia in the world are various, such as the traditional western medicines, such as carbamazepine, phenytoin sodium and the like; surgical treatment methods, such as semilunar ganglion percutaneous radio frequency thermocoagulation treatment, trigeminal and semilunar ganglion sealing operation, microvascular decompression operation, and the like; dietetic therapy, such as avoidance of alcohol consumption, avoidance of irritating foods and consumption of a diet at an appropriate temperature, should be applied to the patient. In addition, traditional Chinese medicine shows the advantages of treating the disease. In traditional Chinese medicine, diseases such as migraine, headache and the like are similar to prosopalgia. The traditional Chinese medicine considers that the prosopalgia is caused by three yang meridians and tendons affected by pathogenic factors. Ancient cloud: the peak is above the apex but wind can be seen, which is similar to the behavior of wind-evil patients and accumulates much experience in treatment according to the characteristics of pain attack. Ming Jingyue quan Shu (Jingyue complete book) Yue: for headache, the physician should treat the headache temporarily before the treatment, and then the exterior and interior of the flap. For transient disease, pathogenic factors must be: for long-term disease, it is necessary to reduce the original qi. For the patients with temporary diseases and exogenous pathogenic factors, the treatment should be dispersed if the pathogenic wind-cold is in the channels, the pathogenic wind-cold is most prohibited to be lifted and dispersed, and the treatment method for the pathogenic factor also plays a strong role in treating the trigeminal neuralgia, for example, the traditional Chinese medicine contains various components and targets various protein targets, so that the development of the medicine based on the traditional Chinese medicine composition has the advantages of reducing side effects, reducing sequelae, taking effect quickly and the like.

Disclosure of Invention

The invention aims to provide a traditional Chinese medicine composition for treating trigeminal neuralgia and application thereof, aiming at overcoming the defects of the existing medicines or treatment methods.

The invention is realized in such a way that a traditional Chinese medicine composition for treating prosopalgia comprises the following components in parts by mass: 1-10 parts of radix aconiti sinomontani (Aconitum sinomontanum), 1-10 parts of rhizoma typhonii (Polygonatum kingianum), 1-10 parts of radix phyllostachys (Cynanchum paniculatum), 1-10 parts of radix notoginseng (sargentgloryvine stem), 1-10 parts of rhizoma gastrodiae, 1-10 parts of radix angelicae, 1-10 parts of asarum, 1-10 parts of scorpion and 1-10 parts of stiff silkworm.

Preferably, the composition comprises the following components in parts by mass: 10 parts of radix aconiti sinomontani (aconitum sinomontanum), 10 parts of rhizoma coptidis (rhizoma polygonati), 10 parts of panax notoginseng (paniculate swallowwort root), 10 parts of radix notoginseng (sargentgloryvine stem), 10 parts of rhizoma gastrodiae, 10 parts of radix angelicae, 10 parts of asarum, 10 parts of scorpion and 3 parts of stiff silkworm.

Preferably, the composition comprises the following components in parts by mass: 3 parts of radix aconiti sinomontani (aconitum sinomontanum), 3 parts of rhizoma coptidis (rhizoma polygonati), 3 parts of panax notoginseng (paniculate swallowwort root), 3 parts of radix notoginseng (sargentgloryvine stem), 3 parts of rhizoma gastrodiae, 3 parts of radix angelicae, 2 parts of asarum, 2 parts of scorpion and 1 part of stiff silkworm.

Preferably, the composition comprises the following components in parts by mass: 3 parts of radix aconiti sinomontani (aconitum sinomontanum), 3 parts of rhizoma coptidis (rhizoma polygonati), 3 parts of panax notoginseng (paniculate swallowwort root), 3 parts of radix notoginseng (sargentgloryvine stem), 3 parts of rhizoma gastrodiae, 3 parts of radix angelicae, 3 parts of asarum, 3 parts of scorpion and 1 part of stiff silkworm.

The invention further discloses application of the traditional Chinese medicine composition in serving as or preparing a medicine for treating trigeminal neuralgia.

Preferably, the dosage form of the medicine comprises decoction, pills, powder, granules, tablets, capsules and oral liquid.

The invention overcomes the defects of the prior art and provides a traditional Chinese medicine composition for treating trigeminal neuralgia and application thereof. In the medicinal composition, the radix aconiti sinomontani (aconitum sinomontanum) can relieve spasm, warm yang, dispel cold and relieve pain; rhizoma Polygoni Cuspidati (rhizoma Polygonati) has effects of invigorating qi and nourishing yin; the panax notoginseng (paniculate swallowwort root) has better effects of dispelling wind and relieving pain; radix Notoginseng (caulis Sargentodoxae) has effects in dredging meridian passage, removing blood stasis, regulating qi-flowing, and promoting blood circulation; rhizoma Gastrodiae has effects of calming endogenous wind, relieving spasm, suppressing liver yang, dispelling pathogenic wind, and dredging collaterals; the radix angelicae has the functions of promoting blood circulation and relieving pain; herba asari can promote diuresis and induce resuscitation; scorpio can be used for treating spasm, convulsion, rheumatism, obstinate arthralgia, migraine and headache; bombyx Batryticatus has effects of calming endogenous wind, relieving spasm, dispelling pathogenic wind, relieving pain, eliminating phlegm, and resolving hard mass. The Chinese medicinal composition has effects of ascending head and eyes, dredging collaterals, relieving spasm, dispelling pathogenic wind, relieving pain, promoting blood circulation, dredging channels, and treating headache and facial pain without impairment of body fluid.

Compared with the defects and shortcomings of the prior art, the invention has the following beneficial effects: the traditional Chinese medicine composition adopts natural traditional Chinese medicines as raw materials, combines seven medicines of Qinling mountain, namely Chinese herbal medicines evolved from Qin mountain, has simple compatibility and preparation process, no toxic or side effect, short treatment course and lower cost, can effectively cure trigeminal neuralgia, is not easy to relapse, and has the effective rate of 98%.

Drawings

FIG. 1 is a comparison of mechanical pain thresholds at different time points after drug administration in 5 groups of rats;

FIG. 2 is a comparison of Glu protein expression levels 8 weeks after administration to 5 groups of rats;

FIG. 3 is a graph showing comparison of the expression levels of inflammatory factor protein in 5 groups of rats after 8 weeks of administration.

Detailed Description

In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.

Example 1 preparation of a medicinal decoction

The medicinal materials comprise the following components in proportion: 10 g of radix aconiti sinomontani, 10 g of rhizoma polygonati, 10 g of panax notoginseng (paniculate swallowwort root), 10 g of panax notoginseng (sargentgloryvine stem), 10 g of rhizoma gastrodiae, 10 g of radix angelicae, 10 g of asarum, 10 g of scorpion and 3 g of stiff silkworm.

(1) Processing the medicinal materials, namely cleaning, cutting and processing the selected Chinese herbal medicines into the decoction pieces meeting the standard.

(2) The method selects good Chinese herbal medicines, quickly removes impurities mixed in the medicinal materials and non-medicinal parts such as soil, gravels, foreign matters, mildewed and rancid of dust and the like by an ultrasonic cleaning technology for 5 minutes, and achieves the purposes of purifying the quality of medicines and reducing the introduction of unidentified substances into organisms.

(3) Decocting Chinese medicinal materials with water and fire

The cleaned Chinese herbal medicines are just immersed on the surface of the medicines by sterile distilled water, soaked for about 30 minutes and properly stirred (residual chlorine in common tap water is accelerated to react with organic substances in raw water when the water is boiled, and carcinogenic substance trichloromethane is probably generated by heating), so that the purposes of softening the medicines, adjusting the medicine property, easily separating out effective components in the medicines and enhancing the curative effect are achieved.

After soaking, adding water 3cm higher than the surface of the medicine (the water addition amount is 600mL), decocting the traditional Chinese medicine in an enamel container, when the temperature of the liquid medicine is rapidly raised to 100 ℃ by sharp fire, properly and continuously turning over the liquid medicine in the decocting process so as to be beneficial to uniformly heating and dissolving out effective components, turning off the fire after the liquid medicine is boiled, and keeping the water slightly boiling for 30 minutes until the liquid medicine is decocted. The liquid medicine is preferably concentrated to 200-250 mL, when the traditional Chinese medicine is decocted, part of the medicine needs to be added later, according to the unique characteristics of the part of the medicine, the effective components are fully utilized, such as angelica dahurica and asarum in the formula are placed in a container after the water is boiled for 20 minutes, the water is kept to slightly boil for 10 minutes, the fire can be turned off, the decoction is completed, and then the supernatant is taken for later use.

One dose is taken every day.

EXAMPLE 2 preparation of granules

The medicinal materials comprise the following components in proportion: 1000g of radix aconiti kusnezoffii (aconitum sinomontanum), 450 g of rhizoma coptidis preparata (rhizoma polygonati), 450 g of panax gracilistylus (paniculate swallowwort root), 450 g of radix notoginseng (sargentgloryvine stem), 450 g of rhizoma gastrodiae, 450 g of radix angelicae, 450 g of asarum, 450 g of scorpion and 135 g of stiff silkworm.

(1) Combining the nine medicines, adding purified water, decocting for 2 times, each time for 2 hours, combining decoctions, filtering, concentrating the filtrate to a relative density of about 1.08-1.10 (90-95 ℃), and cooling to room temperature.

(2) Adding equal amount of ethanol to precipitate, and standing; and (3) concentrating the supernatant to a relative density of 1.20 (55-65 ℃), adding 40% of water, stirring, and standing for 24 hours.

(3) Concentrating the supernatant into clear paste with the relative density of 1.25-1.28 (55-65 ℃).

(4) Drying the concentrated solution by using a belt type vacuum dryer, setting the temperature of the belt type vacuum dryer to be 99 ℃, 95 ℃ and 100 ℃ for 2 hours, crushing the dried solid into fine powder, sieving the fine powder by using a 80-mesh sieve, uniformly mixing the fine powder with a proper amount of conventional auxiliary materials, and granulating the mixture to obtain 1000g of the powder.

The daily dose for a person is as follows: 15-20 g.

EXAMPLE 3 preparation of pharmaceutical tablets

The medicinal materials comprise the following components in proportion: 150 g of radix aconiti sinomontani, 150 g of rhizoma polygonati, 150 g of panax notoginseng (paniculate swallowwort root), 150 g of panax notoginseng (sargentgloryvine stem), 150 g of rhizoma gastrodiae, 150 g of radix angelicae, 150 g of asarum, 150 g of scorpion and 45 g of stiff silkworm.

(1) Extraction: extracting the nine medicinal materials with water, adding 10 times of water, decocting and extracting for 2 times, each time for 2 hr, filtering to obtain filtrate, and mixing filtrates obtained by multiple water extractions;

(2) concentrating an extracting solution: concentrating the combined extracting solution to obtain a concentrated solution, wherein the concentration temperature is 55-70 ℃, and the relative density of the concentrated solution is 1.08-1.10 when the concentrated solution is concentrated to 50 ℃;

(3) alcohol precipitation: cooling the concentrated extract to room temperature, adding 95% ethanol to make the ethanol content reach 60%, standing for 24 hr, and collecting the supernatant;

(4) concentrating the supernatant after alcohol precipitation: concentrating the supernatant of the alcohol precipitation to obtain a concentrated solution, wherein the concentration temperature is 55-65 ℃, and the relative density of the concentrated solution is 1.25-1.28 when the concentrated solution is concentrated to 50 ℃;

(5) and (3) drying: drying the concentrated solution with a belt vacuum drier at 99 deg.C, 95 deg.C and 100 deg.C for 2 hr, pulverizing the dried solid into fine powder, sieving with 80 mesh sieve, mixing with conventional adjuvants, granulating, and tabletting to obtain 1000 tablets.

EXAMPLE 4 preparation of pharmaceutical capsules

The medicinal materials comprise the following components in proportion: 120 g of radix aconiti sinomontani, 120 g of rhizoma polygonati, 120 g of panax notoginseng (paniculate swallowwort root), 120 g of panax notoginseng (sargentgloryvine stem), 120 g of rhizoma gastrodiae, 120 g of radix angelicae, 120 g of asarum, 120 g of scorpion and 36 g of stiff silkworm.

(1) Extraction: extracting the above nine medicinal materials with water, adding 10 times of water, decocting for 2 times, each time for 2 hr, filtering to obtain filtrate, and mixing filtrates obtained by multiple water extractions.

(2) Concentrating an extracting solution: and concentrating the combined extracting solution to obtain a concentrated solution, wherein the concentration temperature is 55-70 ℃, and the relative density is 1.08-1.10 when the concentrated solution is concentrated to 50 ℃.

(3) Alcohol precipitation: cooling the concentrated extract to room temperature, adding 95 vol% ethanol to reach ethanol content of 60%, standing for 24 hr, and collecting supernatant after ethanol precipitation.

(4) Concentrating the supernatant after alcohol precipitation: and concentrating the supernatant obtained by alcohol precipitation to obtain a concentrated solution, wherein the concentration temperature is 55-65 ℃, and the relative density of the concentrated solution is 1.25-1.28 when the concentrated solution is concentrated to 50 ℃.

(5) And (3) drying: drying the concentrated solution with a belt vacuum drier at 99 deg.C, 95 deg.C and 100 deg.C for 2 hr, pulverizing the dried solid into fine powder, sieving with 80 mesh sieve, mixing with conventional adjuvants, granulating, and encapsulating to obtain 1000 granules.

EXAMPLE 5 preparation of pills (honeyed pills)

The medicinal materials comprise the following components in proportion: 450 g of radix aconiti sinomontani, 450 g of rhizoma polygonati, 450 g of panax gracilistylus, 450 g of radix cynanchi paniculatae, 450 g of radix notoginseng pentandrae, 450 g of rhizoma gastrodiae, 450 g of radix angelicae, 450 g of asarum, 450 g of scorpion and 135 g of stiff silkworm.

(1) The nine ingredients are crushed into fine powder and sieved by a 80-mesh sieve for later use.

(2) Refining honey: weighing a certain amount of honey, heating in an evaporating dish until the honey is boiled (impurities can be filtered), continuously refining to obtain refined honey, and removing floating foam with luster.

(3) Mixing the medicines: the refined honey is mixed with the dried solid in example 2, and the mixture is pulverized into fine powder according to the proportion (the proportion of the medicinal powder to the refined honey is 1: 1 generally).

(4) Preparing strips and pills: and (3) placing the well-combined dough-like soft material for a certain time to ensure that the medicine materials and the honey components are mixed and moistened, and rubbing the dough into strips after certain viscosity is generated, wherein the rubbing strips are consistent in thickness and smooth in appearance. The pills can be made into certain amount of smooth round spherical pills by hand or by a pill making plate, and can also be made into pills by machinery.

(5) Packaging and storing: the honeyed pill can be packaged with cellophane, wax paper, plastic bag, and wax shell, and stored in dry place in shade with name, specification, and batch number.

EXAMPLE 6 preparation of powders

The medicinal materials comprise the following components in proportion: 10 g of radix aconiti sinomontani, 10 g of rhizoma polygonati, 10 g of panax notoginseng (paniculate swallowwort root), 10 g of panax notoginseng (sargentgloryvine stem), 10 g of rhizoma gastrodiae, 10 g of radix angelicae, 10 g of asarum, 10 g of scorpion and 100 g of stiff silkworm.

(1) Crushing and sieving: according to the properties of the medicament and the requirements of clinical medication, a proper crushing method is adopted for crushing and sieving to obtain fine powder for later use;

(2) mixing: so that the solid powders are mutually cross-dispersed. By the operation, various medicines in the powder are uniformly mixed and have consistent color and luster; the mixing method generally includes a grinding mixing method, a stirring mixing method and a sieving mixing method. A small amount of the preparation is mixed by grinding and then sieving; the mass preparation adopts the modes of stirring, sieving and mixing after stirring and sieving;

(3) the divided dose is as follows: the divided dosage refers to the operation of dividing the powder which is evenly mixed into equal parts by weight according to the required dosage;

(4) packaging: the powder has large specific surface area, is easy to agglomerate, absorb moisture, even change color and decompose, thereby influencing the curative effect and the taking; therefore, suitable packaging materials and storage conditions should be selected to retard the moisture absorption of the powder. Common packaging materials comprise glossy paper, cellophane, wax paper, plastic bottles, glass bottles, hard capsules, aluminum plastic bags, polyethylene plastic film bags and the like; the dosage-distributing powder can be packaged by various medicine paper bags, multi-purpose paper boxes for non-dosage-distributing powder and glass bottles. The powder should be stored in a cool and dry environment, classified for storage, and inspected regularly.

Example 7

This example is substantially the same as example 6, except that the ratio of the herbs is different. Specifically, the medicinal materials of the embodiment comprise the following components in proportion: 100 g of radix aconiti sinomontani, 100 g of rhizoma polygonati, 100 g of panax gracilistylus, 100 g of radix cynanchi paniculatae, 100 g of radix sargentodoxae, 100 g of rhizoma gastrodiae, 100 g of radix angelicae, 100 g of asarum, 100 g of scorpion and 10 g of stiff silkworm.

Example 8

This example is substantially the same as example 6, except that the ratio of the herbs is different. Specifically, the medicinal materials of the embodiment comprise the following components in proportion: 100 g of radix aconiti sinomontani, 100 g of rhizoma polygonati, 100 g of panax gracile, 100 g of paniculate swallowwort root, 100 g of radix notoginseng, 100 g of rhizoma gastrodiae, 100 g of radix angelicae, 100 g of asarum, 100 g of scorpion and 30 g of stiff silkworm.

Example 9

This example is substantially the same as example 6, except that the ratio of the herbs is different. Specifically, the medicinal materials of the embodiment comprise the following components in proportion: 300 g of radix aconiti sinomontani, 300 g of rhizoma polygonati, 300 g of panax notoginseng (paniculate swallowwort root), 300 g of panax notoginseng (sargentgloryvine stem), 300 g of rhizoma gastrodiae, 300 g of radix angelicae, 200 g of asarum, 200 g of scorpion and 100 g of stiff silkworm.

Example 10

This example is substantially the same as example 6, except that the ratio of the herbs is different. Specifically, the medicinal materials of the embodiment comprise the following components in proportion: 300 g of radix aconiti sinomontani, 300 g of rhizoma polygonati, 300 g of panax notoginseng (paniculate swallowwort root), 300 g of panax notoginseng (sargentgloryvine stem), 300 g of rhizoma gastrodiae, 300 g of radix angelicae, 300 g of asarum, 300 g of scorpion and 100 g of stiff silkworm.

Effect example 1 drug efficacy test

1. Experimental Material

(1) The test drugs are: the decoction obtained was prepared according to the method of example 1;

(2) experimental animals: adult healthy Wistar rats weighing 250 g;

(3) experimental reagent: molding reagent: 10% chloral hydrate and 30% talcum powder suspension;

(4) the main experimental apparatus: von Frey pain measuring instrument.

2. Molding die

(1) The rats were weighed and anesthetized with 50mg/kg of 1% sodium pentobarbital. For the drug combination model group, experimental rats were subjected to intraperitoneal anesthesia using 10% chloral hydrate. After the anesthesia effect is achieved, the head and four limbs of the rat are fixed, the infraorbital region of the operation side is disinfected by 3% iodophor, the needle inlet point is positioned about 1cm beside the nasal alar of the rat, and the connecting line of the needle inlet point and the inner canthus of the eye is perpendicular to the connecting line of the nasal alar and the tragus. After the syringe is inserted from the needle insertion point, the patient is probed and inserted into the infraorbital foramen, and 0.3mL of 30% talcum powder suspension or 0.3mL of 0.9% physiological saline is respectively injected. The whole process should be operated aseptically.

(2) Adaptive breeding of rats for one week

Randomly divided into five groups: normal group, model group, example 1 low dose group, example 1 medium dose group, example 1 high dose group, 15/group. The blank group and the model group were given the same volume of the corresponding solvent at the same time, and the three dose groups were given once a day, gavaged, and continuously given for 8 weeks.

3. Experimental data acquisition and result determination

(1) Animal experiment data acquisition method

Animal behavioral testing: rats were placed in metal grid cages and acclimatized for 10 minutes prior to testing. According to Christensen et al, rats were stimulated with surgical palpation pad areas at intensities of 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0 and 12.0g, with the Von Frey membranes slowly approaching the rats, with the two stimulations separated by at least 10 s.

(2) Determination of animal experiment results

The mechanical pain threshold measured at this time was recorded when the following positive reactions occurred: A. attack behavior: the rat is in an irritation state, and makes an attacking behavior of scratching a Von Frey films tester; B. scratching behavior: making more than three continuous face scratching actions on the stimulation part; C. withdrawal behavior: to avoid irritation, rats would hide in a corner or under the material. If a maximum intensity of 12.0g of rats is used without a positive response, the threshold value for this assay is 12.0 g.

Pain threshold measurements were performed 3 days before injection, 3 days, 1 week, 2 weeks, 4 weeks, and 8 weeks after injection, respectively, on both groups and the results were recorded.

4. Results

As shown in figure 1, the mechanical pain threshold values of 5 groups of rats after administration are compared at different time points (n is 15, g, (x +/-s).) and the mechanical pain threshold values of 3 days before administration are 10.33 +/-0.78 g of a blank group, 3.53 +/-0.96 g of a model group, 3.85 +/-0.96 g of a low dose, 3.21 +/-0.87 g of a medium dose, 3.53 +/-0.98 g of a high dose, no statistical difference (p is greater than 0.05) and no significant difference in five groups, and the pain threshold values of the rats in the administration group are significantly increased (p is less than 0.01) after three days to 4 weeks after administration, so that the mechanical pain threshold values of the rats in the administration group are significantly increased compared with the rats in the model group from the data point of view, which shows that the traditional Chinese medicine composition can effectively treat and relieve trigeminal neuralgia of the rats.

Effect example 2 histological analysis

Glu is an important neurotransmitter distributed in the nervous system and is widely involved in the regulation of various nerves. Under physiological conditions, extracellular Glu clearance and recirculation mainly depend on glutamic acid-glutamine circulation, can ensure sensitivity of synaptic transmission and also provide precursor substances for synthesis of Glu in neurons. Glu transporter function or glutamine synthetase dysfunction can lead to excessive accumulation of extracellular Glu and blocking of glutamate-glutamine circulation, act on neuronal NMDA receptors, and lead to sustained activation of neurons, which may be involved in trigeminal neuralgia. The trigeminal ganglion is the cell body of the primary afferent neuron of the trigeminal nerve, wherein the satellite glial cell plays a role in clearing excitatory amino acid-glutamic acid and can avoid the continuous activation of the primary afferent neuron. Glu is a key transmitter responsible for transmission and regulation of oral and facial sensory information, and is widely expressed on the whole trigeminal sensory transmission pathway. Early clinical application also adopted Glu receptor blockers acting on postsynaptic membranes to intervene in orofacial pain caused by trigeminal nerves, and achieved good results.

1. Experimental data acquisition and result determination

(1) Animal experiment data acquisition method

After each group of rats completed the pain threshold test, they were sacrificed by cervical dislocation; the thoracic cavity and cranial cavity were opened, the trigeminal tissue was removed, placed in 16g/L formaldehyde, gradient dehydrated for tissue embedding, and cut into sheets of about 6 μm. The Glu expression in trigeminal ganglion cells is detected by immunohistochemistry, pictures are photographed by a microscope and optical density values (OD) are quantitatively analyzed, and cytoplasm and cell membranes of Glu positive expression are dyed into tan.

(2) Analysis of animal Experimental results

The Glu expression in trigeminal ganglion cells is detected by immunohistochemistry, pictures are photographed by a microscope and optical density values (OD) are quantitatively analyzed, and cytoplasm and membranes of Glu positive expression are dyed into tan.

2. Results

As shown in fig. 2, the comparison of Glu protein expression levels after 8 weeks of administration to 5 groups of rats (n ═ 7, (x ± s).) shows that the expression of Glu protein in cells of trigeminal ganglia of the rats in the model group is higher than that of the rats in the significant control group, and has significant difference (p < 0.01). the intracellular Glu protein expression of rats in the medium dose group is significantly reduced compared with those in the model group (p > 0.05). from the data, the intracellular Glu protein expression of rats in the medium dose group is most significant, which indicates that the above traditional Chinese medicine combination can effectively treat and relieve trigeminal neuralgia of rats.

Effect example 3 detection of IL-1. beta. and NF-. kappa.B protein expression in rat trigeminal ganglia

The expression levels of IL-1 beta and NF-kB proteins of trigeminal ganglion inflammatory factors of rats in each group are detected by adopting an immune protein blotting method (Western blotting).

1. Experimental data acquisition and result determination

(1) Experimental data acquisition method

After each group of rats completed the pain threshold test, they were sacrificed by cervical dislocation; separating trigeminal ganglia of rats by surgical treatment; extracting protein, quantifying by using a bicinchoninic acid (BCA) protein, and then carrying out electrophoresis treatment on sodium dodecyl sulfate-polyacrylamide gel, membrane conversion, sealing, incubation and color development treatment.

(2) Analysis of Experimental results

Grayscale analysis was performed using software Image J.

2. Results

As shown in fig. 3, the levels of the inflammatory factor protein were compared after 8 weeks of administration to the rats in the 5 groups (n ═ 8, (x ± s). compared with the blank group, the levels of IL-1 β and NF- κ B protein expression in trigeminal ganglia of the rats in the model group were significantly increased (P <0.01), and the levels of IL-1 β and NF- κ B protein expression in the administered group were significantly decreased (P <0.01) compared with the model group.

The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.

Claims

1. The traditional Chinese medicine composition for treating prosopalgia is characterized by comprising the following components in parts by mass: 1-10 parts of radix achyranthis bidentatae, 1-10 parts of radix aconiti agrestis, 1-10 parts of radix notoginseng lophatheri, 1-10 parts of radix notoginseng pentandrae, 1-10 parts of rhizoma gastrodiae, 1-10 parts of radix angelicae, 1-10 parts of asarum, 1-10 parts of scorpion and 1-10 parts of stiff silkworm.

2. The traditional Chinese medicine composition as claimed in claim 1, wherein the composition comprises the following components in parts by mass: 10 parts of radix notoginseng, 10 parts of rhizoma coptidis, 10 parts of rhizoma phyllanthi, 10 parts of radix notoginseng, 10 parts of rhizoma gastrodiae, 10 parts of radix angelicae, 10 parts of asarum, 10 parts of scorpion and 3 parts of stiff silkworm.

3. The traditional Chinese medicine composition as claimed in claim 1, wherein the composition comprises the following components in parts by mass: 3 parts of radix notoginseng, 3 parts of rhizoma coptidis, 3 parts of rhizoma polygoni multiflori, 3 parts of rhizoma gastrodiae, 3 parts of radix angelicae, 2 parts of asarum, 2 parts of scorpion and 1 part of stiff silkworm.

4. The traditional Chinese medicine composition as claimed in claim 1, wherein the composition comprises the following components in parts by mass: 3 parts of radix notoginseng, 3 parts of rhizoma coptidis, 3 parts of rhizoma polygoni multiflori, 3 parts of rhizoma gastrodiae, 3 parts of radix angelicae, 3 parts of asarum, 3 parts of scorpion and 1 part of stiff silkworm.

5. The use of the Chinese medicinal composition of any one of claims 1 to 4 as or in the preparation of a medicament for the treatment of trigeminal neuralgia.

6. The use of claim 5, wherein the medicament is in the form of decoction, pill, powder, granule, tablet, capsule, or oral liquid.